Kontrazeption und Adipositas

Die Kontrazeption bei Patientinnen mit einer Adipositas stellt eine klinisch spezielle Situation dar. Das erhöhte Risiko für venöse Thrombembolien ist zu beachten. Außerdem können spezielle Nebenwirkungen von Kontrazeptionsmethoden auftreten, und auch die Sicherheit einzelner Kontrazeptionsmethoden ist eingeschränkt. Die Wahl der Kontrazeptionsmethode bei adipösen Patientinnen bedarf einer individuellen Lösung – der Beitrag gibt einen Überblick, wie vorzugehen und was zu beachten ist.

Publication History

Article published online:
29 May 2024

• Literatur

• 1 Schienkiewitz A, Mensink G, Kuhnert R. et al. Übergewicht und Adipositas bei Erwachsenen in Deutschland. J Health Monit 2017;
• 2 AWMF S3-Leitlinie „Hormonelle Empfängnisverhütung“. Nr. 015-015 (September 2020).
• 3 Mody S, Han M. Obesity and Contraception. Clin Obstet Gynecol 2014; 57: 501-507
• 4 FSRH. FSRH-Guideline: Overweight, Obesity & Contraception. Online (Stand: 18.03.2021): https://www.fsrh.org/standards-and-guidance/documents/fsrh-clinical-guideline-overweight-obesity-and-contraception/
• 5 Gallo MF, Lopez LM. et al. Combination contraceptives: Effects on weight. Cochrane Database Syst Rev 2014; (01) CD003987
• 6 Beksinska ME, Smit JA, Guidozzi F. Weight change and hormonal contraception: Fact and fiction. Expert Rev Obstet Gynecol 2011; 6: 45-56
• 7 Römer T, Göretzlehner G. Kontrazeption mit OC in 238 Problemsituationen. 3rd ed.. ed. Berlin: De Gruyter; 2017: 3-320
• 8 Pomp ER, Le Cessie S, Rosendaal FR. et al. Risk of thrombosis: Obesity and ist joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 286-296
• 9 WHO Department of Reproductive Health. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: WHO; 2015
• 10 Bundesinstitut für Arzneimittel und Medizinprodukte. Rote-Hand-Brief zur kombinierten hormonalen Kontrazeptiva. Online (Stand: 23.09.2019): http://www.bfarm.de/Shared.Docs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2014/rhb-khk.html
• 11 Römer T. Kontrazeption bei Patienten mit Risikokonstellation. Dtsch Arztebl Int 2019; 116: 764-774
• 12 Ciprani S, Todisco T, Scavello I. et al. Obesity and hormonal contraception: An overview and a clinicanʼs practical guide. Eat Weight Disord 2020; 25: 1129-1140
• 13 Sundelt M, Ginstman C, Mansson A. et al. Patterns of prescription and discontinuation of contraceptives for Swedish women with obesity and normal-weight women. Eur J Concept Reprod Health Car 2019; 24: 193-197
• 14 Holt VL, Scholes D, Wicklund KG. et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46-52
• 15 Jusko WJ. Clarification of contraceptive drug pharmacokinetics in obesity. Contraception 2017; 95: 10-16
• 16 Simmons K, Edelman A. Hormonal contraception and obesity. Fertil Steril 2016; 106: 1282-1288
• 17 Burkman RT, Fisher AC, Wan GJ. et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79: 424-427
• 18 Ramandhan S, Jusko WJ, Edelman A. Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: A Review. Curr Obstet Gynecol Rep 2020; 9: 72-78
• 19 Lopez L, Bernholc A, Chen M. et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2016; 2016 (08) CD008452
• 20 Dinger JC, Cronin M, Möhner S. et al. OC effectiveness according to BMI, weight, age and other factors. Am J Obstet Gynecol 2009; 201: 263-269
• 21 Zieman M, Guillebaud J, Weisberg E. et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: A analysis of pooled data. Fertil Steril 2002; 77 (2 Suppl. 2): S13-S18
• 22 Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception 2009; 80: 346-354
• 23 Xu H, Wade JA, Peipert JF. et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese Women. Obstet Gynecol 2012; 120: 21-26
• 24 Jatlaoui TC, Curtis KM. Safety and effectiveness data for emergency contraceptive pills among women with obesity: A systematic review. Contraception 2016; 94: 605-611
• 25 Praditpan P, Hamoui A, Basaraba C. et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception 2017; 95: 464-469
• 26 Curtis KM, Tepper NK, Jatloui TC. et al. U.S. Medical Eligibility Criteria for Contraceptive Use 2016. MMWR Recomm Rep 2016; 6: 103
• 27 Cleland K, Raymond E, Westley E. et al. Emergency contraception review: Evidence-based recommendation for clinicians. Clin Obstet Gynecol 2014; 57: 741-750
• 28 Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: A multicenter clinical trial. Contraception 2001; 64: 107-112
• 29 Menke M, King W, White G. et al. Contraception and Conception After Bariatric Surgery. Obstet Gynecol 2017; 130: 979-987
• 30 Parent B, Martopullo I, Weiss NS. et al. Bariatric Surgery in Women of Childbearing Age, Timing Between an Operation and Birth, and Associated Perinatal Complications. JAMA Surg 2017; 152: 128-135
• 31 Graham Y, Mansour D, Small P. et al. A Survey of Bariatric Surgical and Reproductive Health Professionals Knowledge and Provision of Contraception to Reproductive – Aged Bariatric Surgical Patients. Obes Surg 2016; 26: 1918-1923
• 32 Mengesha B, Carter J, Dehlendorf C. et al. Perioperative pregnancy interval, contraceptive couseling experiences, and contraceptive use in women undergoing bariatric surgery. Am J Obstet Gynecol 2018; 219: 81.e1-81.e9
• 33 Luyssen J, Jans G, Bogaerts A. et al. Contraception, Menstruation, and Sexuality after Baratric Surgery: A Prospective Cohort Study. Obes Surg 2018; 28: 1385-1393
• 34 Ginstman C, Frisk J, Ottosson J. et al. Contraceptive Use Before and After Gastric Bypass: A Questionnaire Study. Obes Surg 2015; 25: 2066-2070
• 35 Damhof M, Pierik E, Krens L. et al. Assessment of Contraceptive Counseling and Contraceptive Use in Women After Bariatric Surgery. Obes Surg 2019; 29: 4029-4035